Severe neurological crisis in a patient with hereditary tyrosinaemia type I after interruption of NTBC treatment
The DOI matches its Crossref record; 13 of the 14 references it cites were found in a registry or an index.
Abstract
Summary: Neurological crises do not occur in patients with tyrosinaemia type I treated with NTBC. We report an 8 month‐old boy with severe neurological crisis after interruption of NTBC treatment including progressive ascending polyneuropathy and diaphragmatic paralysis, arterial hypertension, respiratory distress requiring mechanical ventilation who later also developed impaired liver function and tubulopathy. After re‐introduction of NTBC the patient slowly regained normal neurological functions and recovered completely.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Failure to do so may precipitate serious complications including acute liver failure, a neurological crisis [21] or even hepatic malignant change.”
From Recommendations for the management of tyrosinaemia type 1 (2013) · cites this paper as [21]
In the citing paper
“Additionally, patients may develop neurological crises in response to discontinuation of NTBC [41].”
From Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice (2014) · cites this paper as [41]
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
The metabolic and molecular bases of inherited disease
Chen, Y.-T. (2001) · Medical Entomology and Zoology · Cited by 6,928
Human Gene Mutation Database (HGMD®): 2003 update: HGMD 2003 UPDATE
Stenson, P. D., Ball, E. V., Mort, M., Phillips, A. D., Shiel, J. A., Thomas, N. S. T., Abeysinghe, S., Krawczak, M., & Cooper, D. N. (2003) · Human Mutation · doi:10.1002/humu.10212 · Cited by 1,829
Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase
LINDSTEDT, S. (1992) · The Lancet · doi:10.1016/0140-6736(92)92685-9 · Cited by 631 · cited 2×
“With NTBC a normalization of toxic metabolites in blood such as succinylacetone and the correction of the almost complete inhibition of porphobilinogen synthase in erythrocytes can be observed, protecting against porphyric crisis ( Lindstedt et al 1992 ).”
BackgroundOn the enzymic defects in hereditary tyrosinemia.
Lindblad, B., Lindstedt, S., & Steen, G. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.10.4641 · Cited by 447
Inborn Metabolic Diseases: Diagnosis and Treatment
(2012) · doi:10.1007/978-3-642-15720-2 · Cited by 377
Neurologic Crises in Hereditary Tyrosinemia
Mitchell, G., Larochelle, J., Lambert, M., Michaud, J., Grenier, A., Ogier, H., Gauthier, M., Lacroix, J., Vanasse, M., Larbrisseau, A., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002153220704 · Cited by 232
Russo, P. A., Mitchell, G. A., & Tanguay, R. M. (2001) · Pediatric and Developmental Pathology · doi:10.1007/s100240010146 · Cited by 220
Van Spronsen, F. J., Thomasse, Y., Smit, P. G. A., Leonard, J. V., Clayton, P. T., Fidler, V., Berger, R., & Heymans, H. S. A. (1994) · Hepatology · doi:10.1002/hep.1840200513 · Cited by 193 · cited 1×
“On dietary treatment alone with restriction of phenylalanine and tyrosine intake, over 90% of patients die before 12 years of age, 10% of them due to a porphyria-like syndrome with respiratory failure (van Spronsen et al 1994).”
BackgroundThe pathophysiology and treatment of hereditary tyrosinemia type 1
Grompe, M. (2001) · Seminars in Liver Disease · doi:10.1055/s-2001-19035 · Cited by 167 · cited 1×
“Fumarylacetoacetate is toxic to liver, leading to raised a-fetoprotein (AFP) early in disease, and to kidney (Grompe 2001; Lindblad et al 1974).”
BackgroundTyrosinemia type I treated by NTBC: How does AFP predict liver cancer?
Koelink, C., van Hasselt, P. M., van der Ploeg, A., van den Heuvel‐Eibrink, M. M., Wijburg, F. A., Bijleveld, C. M. A., & van Spronsen, F. J. (2006) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2006.07.009 · Cited by 65
Disorders of Tyrosine Metabolism
Chakrapani, A., & Holme, E. (2006) · Inborn Metabolic Diseases · doi:10.1007/978-3-540-28785-8_18 · Cited by 52
Evidence for Liver Disease Preceding Amino Acid Abnormalities in Hereditary Tyrosinemia
Hostetter, M. K., Levy, H. L., Winter, H. S., Knight, G. J., & Haddow, J. E. (1983) · New England Journal of Medicine · doi:10.1056/nejm198305263082105 · Cited by 44
Cited by
Recommendations for the management of tyrosinaemia type 1
de Laet, C., Dionisi-Vici, C., Leonard, J. V., McKiernan, P., Mitchell, G., Monti, L., de Baulny, H. O., Pintos-Morell, G., & Spiekerkötter, U. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-8 · Cited by 227
“Failure to do so may precipitate serious complications including acute liver failure, a neurological crisis [21] or even hepatic malignant change.”
BackgroundSelf-citationMayorandan, S., Meyer, U., Gokcay, G., Segarra, N. G., de Baulny, H. O., van Spronsen, F., Zeman, J., de Laet, C., Spiekerkoetter, U., Thimm, E., et al. (2014) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-014-0107-7 · Cited by 131
Self-citationPeripheral neuropathy in complex inherited diseases: an approach to diagnosis
Rossor, A. M., Carr, A. S., Devine, H. E., Hoskote, C., Pelayo‐Negro, A. L., Pareyson, D., Shy, M. E., Scherer, S. S., & Reilly, M. M. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-313960 · Cited by 80
van Ginkel, W. G., Rodenburg, I. L., Harding, C. O., Hollak, C. E. M., Heiner-Fokkema, M. R., & van Spronsen, F. J. (2019) · Pediatric Drugs · doi:10.1007/s40272-019-00364-4 · Cited by 65
Neurological and Neuropsychological Problems in Tyrosinemia Type I Patients
van Ginkel, W. G., Jahja, R., Huijbregts, S. C. J., & van Spronsen, F. J. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55780-9_10 · Cited by 36
Metadata
- Authors
- Schlump, J. ‐., Perot, C., Ketteler, K., Schiff, M., Mayatepek, E., Wendel, U., & Spiekerkoetter, U.
- Affiliations
- Düsseldorf University Hospital (DE)
- Hôpital Robert-Debré (FR)
- Corresponding author
- Schlump, J.‐U.
- Venue
- Journal of Inherited Metabolic Disease
- Publisher
- Wiley
- Published
- 2008-05-20
- Volume
- 31
- Issue
- S2
- Pages
- 223-225
- ISSN
- 0141-8955 (ISSN-L)
- 1573-2665
- OpenAlex
- W2030445180
- Cited by
- 24
- References
- 14
- Citations by year
- 2026: 1 · 2025: 3 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 2 · 2017: 6 · 2016: 2 · 2014: 2 · 2013: 1 · 2012: 1
- FWCI
- 0.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Inherited Metabolic Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- NTBC, treatment interruption, polyneuropathy, diaphragmatic paralysis, hypertension, respiratory distress, liver dysfunction, tubulopathy, tyrosine metabolism disorders
- MeSH terms
- Cyclohexanones, Drug Administration Schedule, Enzyme Inhibitors, Humans, Hypertension, Infant, Male, Nitrobenzoates, Polyneuropathies, Respiration, Artificial, Respiratory Insufficiency, Respiratory Paralysis, Tyrosinemias, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.